Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical executes a directed new share issue to NXT2B immediately followed by a guaranteed preferential rights issue – In total MSEK 46 is raised

Regulatory information

Hansa Medical’s Board of Directors has resolved to notify the shareholders in Hansa Medical of an extraordinary meeting to be held on 9 January 2012. The Board of Directors propose that a directed share issue be executed to Bengt Ågerup’s investment company, NXT2B, amounting 5 million shares at a subscription rate of SEK 5.50 per share, which will provide Hansa Medical with MSEK 27.5. After the executed directed share issue, NXT2B’s shareholding will amount to 27%. Hansa Medical’s Board of Directors also proposes that a fully guaranteed preferential rights issue be executed after the directed new share issue to NXT2B. This proposal implies that 3,704,229 shares will be issued at a subscription rate of SEK 5 per share, which will provide Hansa Medical with a further MSEK 18.5 before new share issue costs. In the preferential rights issue, five existing shares will entitle the right to one new share. Hansa Medical will be provided a total of MSEK 46 before new share issue costs. The preferential rights issue is guaranteed by NXT2B and Farstorp Invest AB, equally. Further details of the new share issue will be provided in the notice of the extraordinary meeting of shareholders, which is expected to be made public next week.

Background and motivation
Hansa Medical has decided to focus its operations on the development of the enzymes IdeS and EndoS. IdeS and EndoS are immunomodulating enzymes with therapeutic applications in rare autoimmune diseases and transplantation. Toxicology studies with IdeS are ongoing and the ambition is to apply for clinical Phase I studies at the Swedish Medical Products Agency in Q1 2012. The Phase 1 study is planned to begin during Q2 2012. A Phase 2 study for IdeS is planned to be initiated in Q1 2013. In the Phase 2 study, IdeS will be used with the primary aim of ensuring that so-called sensitised patients can undergo transplants. Sensitised patients is a patient group which is, today, problematic in terms of transplantation due to high levels of anti-donor antibodies. Raising MSEK 46 secures the financing of Hansa Medical for two years and the goal is to carry out both Phase 1 and Phase 2 studies for IdeS within this time period. In addition, novel therapeutic applications of both IdeS and EndoS will be further developed.

”NXT2B provides major competence and experience within clinical development and commercialisation of new therapeutic concepts. The new share issues make it possible for Hansa Medical to achieve clinical proof-of-concept for IdeS,” states Emanuel Björne, CEO of Hansa Medical AB.

”Hansa Medical is facing a very exciting future based on strong and unique research in combination with a well-balanced development strategy. We are proud to participate in this process.” states Bengt Ågerup,

Preliminary schedule for proposed directed share issue and preferential rights issue
9 January 2012: Extraordinary meeting of shareholders
11 January 2012: Execution of the directed new share issue to NXT2B
23 February 2012: Publication of prospectus regarding the preferential rights issue
29 February 2012: Record day for the receipt of subscription rights in the preferential rights issue
5 March– 19 March 2012: Subscription period for the preferential rights issue
22 March 2012: Public notice of the outcome of the preferential rights issue

Downloads